bimagrumab semaglutide phase 2
Eliminate HbA1c Plateaus With the Secret Dual Obesity Treatment
In a phase 2 trial of 386 participants, the dual therapy of semaglutide and bimagrumab produced a 9.4% BMI reduction and a 1.5% HbA1c drop, surpassing monotherapy outcomes. Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare